Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
The purpose of the study is to determine the influence of GnRH (gonadotropin releasing
 hormone) analogue - Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine) administration
 on intensity of lower urinary tract symptoms (LUTS) in patients with diagnosed locally
 advanced and/or metastatic prostate cancer and LUTS.
The remaining target is:

 - to assess the intensity of LUTS in Polish and Ukrainian patients with locally advanced and
 metastatic prostate cancer, previously untreated with hormonal therapy
Inclusion Criteria:

 -  Age > 50 years

 -  Locally advanced (T3-T4) and/or metastatic (N+/M+) hormone-sensitive prostate cancer,
 confirmed by histological examination

 -  Presence of lower urinary tract symptoms (LUTS)-IPSS >0

 -  Treatment with Lucrin® Depot is the routine therapy in the patient. The decision as to
 Lucrin® Depot choice will not be associated with patient's participation in the study,
 but will result from the best medical knowledge and practice.

 -  Until inclusion into PMOS the patient has not been treated with GnRH analogue.

 -  The patient, before inclusion into the study, has not been treated by surgery (radical
 prostatectomy).

 Exclusion Criteria:

 -  Patients will not be included into the study if any contraindications to treatment
 with Lucrin® Depot exist, or if there are other treatment options which, according to
 the present medical knowledge, are potentially more beneficial for the patient.

 -  Physician or patient can stop treatment at any moment, if any indications or reasons
 exist.